Lyell Immunopharma, Inc. Common Stock (LYEL) is a publicly traded Healthcare sector company. As of July 18, 2026, LYEL trades at $13.34 with a market cap of $340.37M and a P/E ratio of -0.98. LYEL moved -3.96% today. Year to date, LYEL is -56.73%; over the trailing twelve months it is +39.92%. Its 52-week range spans $7.65 to $45.00. Analyst consensus is buy with an average price target of $37.50. Rallies surfaces LYEL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for LYEL combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $13.34 |
| Market Cap | $340.37M |
| P/E Ratio | -0.98 |
| EPS | $-13.80 |
| Dividend Yield | 0.00% |
| 52-Week High | $45.00 |
| 52-Week Low | $7.65 |
| Volume | 155.39K |
| Avg Volume | 0 |
| Revenue (TTM) | $31.00K |
| Net Income | $-246.41M |
| Gross Margin | 0.00% |
4 analysts cover LYEL: 0 strong buy, 3 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $37.50.